Prognostic value of FDG-PET and DWI in breast cancer

Kitajima, Kazuhiro; Miyoshi, Yasuo; Yamano, Toshiko; Odawara, Soichi; Higuchi, Tomoko; Yamakado, Koichiro

doi:10.1007/s12149-017-1217-9

Cited by 39 publications

(41 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DWI, an MRI sequence showing the restricted movement of water molecules in tumoral tissues, was recently introduced as a functional modality to evaluate microstructural characteristics in tumors [ 13 ]. DWI can visualize changes occurring at a cellular spatial scale making it an advantageous tool for evaluating changes in the tumor microenvironment, both before and after NST [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Mooij

Amador

Mitea

et al. 2020

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Mooij

Amador

Mitea

et al. 2020

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Imaging methods, especially mammography, ultrasound and magnetic resonance imaging, play a fundamental role in the diagnosis of BC [2] . Nowadays, also positron emission tomography (PET) is increasingly used in BC [3] , [4] , [5] , [6] , [7] . It has been shown that PET besides detection of distant metastases can also provide additional information about tumor histopathology [5] , [6] , [7] , [8] .…”

Section: Introductionmentioning

confidence: 99%

Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer

Surov

Wienke

2019

Translational Oncology

View full text Add to dashboard Cite

OBJECTIVES: Numerous studies investigated relationships between positron emission tomography and proliferation index Ki-67 in breast cancer (BC) with inconsistent results. The aim of the present analysis was to provide evident data about associations between standardized uptake value (SUV) and expression of Ki-67 in BC. METHODS: MEDLINE library, SCOPUS and EMBASE data bases were screened for relationships between SUV and Ki-67 in BC up to April 2018. Overall, 32 studies with 1802 patients were identified. The following data were extracted from the literature: authors, year of publication, number of patients, and correlation coefficients. Associations between SUV and Ki-67 were analyzed by Spearman's correlation coefficient. RESULTS: Associations between SUVmax derived from 18F-FDG PET and Ki-67 were reported in 25 studies (1624 patients). The pooled correlation coefficient was 0.40, (95% CI = [0.34; 0.46]). Furthermore, 7 studies analyzed associations between SUVmax derived from 18F-fluorthymidin (FLT) PET and Ki-67 (178 patients). The pooled correlation coefficient was 0.54, (95% CI = [0.37; 0.70]). CONCLUSION: SUVmax correlated moderately with expression of Ki-67 and, therefore, cannot be used as a surrogate marker for tumor proliferation. Further studies are needed to evaluate associations between PET parameters and histopathological findings like hormone receptor status in breast cancer.

show abstract

“…Furthermore, the median tumor SUVmax was lower in group 1 than in group 2 patients with cancer (p=0.002). Pretreatment FDG-PET SUV was found to be a prognostic factor for outcome in many types of cancer (32)(33)(34)(35).…”

Section: Discussionmentioning

confidence: 99%

Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

Chan

Liu

Liou

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: Whole-body positron-emission tomography/computed tomography with the glucose analog 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been used to screen examinees for underlying malignancy in many countries. The aim of this study was to compare the potential value of FDG-PET/CT application in asymptomatic individuals with those with suspected malignancy. Patients and Methods: A total of 9,408 examinees underwent wholebody FDG-PET/CT at our hospital from July 2006 to August 2013. Three thousand and seven hundred asymptomatic individuals and 848 individuals with laboratory and clinical/radiologicaI suspicion of malignancy who had undergone FDG-PET/CT for cancer screening were recruited. The final confirmation of cancer and outcomes were based on a pathological report and continuous followup. Results: Forty-five out of 3,700 asymptomatic individuals (1.2%) had proven malignancy, and 42 of them (93.3%) were found by FDG-PET/CT. Two hundred and twelve out of 848 with suspected malignancy (25%) had proven malignancy, and 196 of them (92.5%) were detected by FDG-PET/CT. Most of these cancers in asymptomatic individuals were clinically at an early stage. The discovery rate in asymptomatic individuals and those with suspected malignancy was 1.1% and 23.1%, respectively. The overall survival of patients with cancer diagnosed with PET/CT was higher than those with suspected malignancy (78.6% vs.

show abstract

Prognostic value of FDG-PET and DWI in breast cancer

Abstract: The preoperative SUV, MTV, and TLG of primary breast cancer are prognostic factors for recurrence, whereas ADC values are not.

Cited by 39 publications

References 14 publications

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients

Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer

Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

Contact Info

Product

Resources

About